Core Viewpoint - The company clarifies that it does not hold any direct or indirect equity or investment rights in Sichuan Health Pharmaceutical Co., Ltd., which is involved in the production and distribution of Antarctic krill oil products associated with the "Tong Ren Tang" brand [1] Group 1 - The company has noted reports regarding the Antarctic krill oil products produced by Anhui Habao Pharmaceutical Co., Ltd. and distributed by Beijing Tong Ren Tang (Sichuan) Health Pharmaceutical Co., Ltd. [1] - The company confirms that Sichuan Health Pharmaceutical is not a subsidiary of the company but a holding subsidiary of Tong Ren Tang Group, the company's controlling shareholder [1] - The company is actively communicating with Tong Ren Tang Group to address the situation and jointly maintain the brand image and reputation of "Tong Ren Tang" [1] Group 2 - Tong Ren Tang Group is urging Tong Ren Tang Health to handle the situation in accordance with the law [1] - As of the date of the announcement, the company's medicines are all self-produced, and there is no situation of outsourcing production to external third parties [1]

证券代码：600085 证券简称： 同仁堂 公告编号：2025-041 北京同仁堂股份有限公司 关于相关媒体报道的澄清公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 一、 事件简述 近日，北京同仁堂股份有限公司（以下简称公司或本公司）关注到网络上有关 于安徽哈博药业有限公司生产、北京同仁堂（四川）健康药业有限公司（以下简称 四川健康药业）经销的一款南极磷虾油产品及相关对"同仁堂"品牌的报道。 为避免相关报道对投资者造成误导，公司针对上述事项进行说明并予以澄清。 二、 澄清说明 （一） 关于"同仁堂"商标、字号权属及使用情况 本公司未直接或间接持有南极磷虾油相关报道中提及的四川健康药业任何股 权及投资权益，四川健康药业不属于本公司下属子企业。四川健康药业为公司控股 股东中国北京同仁堂（集团）有限责任公司（以下简称同仁堂集团）下属北京同仁 堂健康药业股份有限公司（以下简称同仁堂健康）的控股子公司。 "同仁堂"商标和"同仁堂"、"北京同仁堂"字号的所有人为同仁堂集团。 本公司及本公司部分子公司获同仁堂集团许可，在商品上使用该商 ...

Core Viewpoint - Tong Ren Tang (600085.SH) issued a statement to clarify its non-involvement with a product related to Antarctic krill oil and to address misleading reports regarding the "Tong Ren Tang" brand [1][2] Group 1: Company Clarification - The company does not hold any direct or indirect equity or investment rights in Sichuan Health Pharmaceutical, which is involved in the production and distribution of the Antarctic krill oil product [1] - Sichuan Health Pharmaceutical is a subsidiary of Beijing Tong Ren Tang Health Pharmaceutical Co., Ltd., which is controlled by the company's major shareholder, Tong Ren Tang Group [1] - The "Tong Ren Tang" trademark and name are owned by Tong Ren Tang Group, which has licensed the use of the trademark to the company and some of its subsidiaries [1] Group 2: Brand Protection Efforts - The company has actively communicated with Tong Ren Tang Group to understand the situation and jointly protect the brand image and reputation [2] - Tong Ren Tang Group is urging Tong Ren Tang Health to handle the situation in accordance with the law [2]

Core Viewpoint - The article highlights the issue of counterfeit products using the "Beijing Tongrentang" brand, specifically a shrimp oil product falsely marketed as having high purity but containing no actual shrimp oil. This situation raises concerns about brand integrity and consumer protection in the e-commerce space [1]. Group 1: Brand Integrity and Consumer Trust - A product claiming to be "Beijing Tongrentang 99% high purity Antarctic shrimp oil" was found to contain 0% shrimp oil, misleading consumers who associate the brand with quality [1]. - The product was sold in large quantities, with reports indicating 5 million units sold on e-commerce platforms, showcasing the scale of the issue [1]. - The company, Beijing Tongrentang Health Pharmaceutical Co., Ltd., has initiated legal action against the infringing company, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd., to protect its brand reputation [1]. Group 2: Regulatory and Management Concerns - The infringing company claims ignorance regarding the misleading packaging, attributing the decision to the manufacturer, Anhui Habao Pharmaceutical Co., Ltd., which has a history of administrative penalties for non-compliance [1]. - The manufacturer’s pricing strategy, with an ex-factory price significantly lower than reasonable cost estimates, raises questions about the legitimacy of the product and the awareness of the infringing company [1]. - The article emphasizes the need for better brand management and quality control within the parent company, as the infringing entity is a subsidiary, indicating potential flaws in oversight [1]. Group 3: E-commerce and Market Regulation - The article describes a chaotic "Tongrentang universe" in e-commerce, where various products mislead consumers by prominently displaying the "Beijing Tongrentang" name while being produced by unrelated companies [1]. - It calls for stronger regulatory measures to protect consumers and uphold the integrity of established brands, suggesting that both the brand owner and regulatory bodies must work together to combat counterfeit products [1]. - The ongoing issue of counterfeit products in the market, including those imitating other reputable brands, highlights the need for vigilance and proactive measures to safeguard consumer rights [1].

Core Viewpoint - Tongrentang issued a clarification announcement regarding online reports about its Antarctic krill oil products and related brand situations, emphasizing that it does not hold any equity or investment rights in Sichuan Health Pharmaceutical, which is not a subsidiary of Tongrentang but rather a part of its controlling shareholder, Tongrentang Group [1] Group 1 - Tongrentang clarified that it does not directly or indirectly hold any equity or investment rights in Sichuan Health Pharmaceutical [1] - Sichuan Health Pharmaceutical is not a subsidiary of Tongrentang but is under the Tongrentang Group [1] - The company emphasized that all its medicines are self-produced and that there is no outsourcing to third parties for production [1] Group 2 - Consumers are advised to identify Tongrentang products through the "Tongrentang Shuanglong trademark" and the production unit labeling [1]

Core Viewpoint - The company clarifies its non-ownership of Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. and emphasizes its focus on self-produced traditional Chinese medicine products [1] Group 1 - The company has responded to recent online reports regarding Anhui Habao Pharmaceutical's production and the Antarctic krill oil products associated with the "Tongrentang" brand [1] - The company does not hold any equity in Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd., which is a subsidiary of its controlling shareholder, Tongrentang Group [1] - The "Tongrentang" trademark and name are owned by Tongrentang Group, and the company, along with some subsidiaries, is authorized to use them [1] Group 2 - The company emphasizes that it focuses on the production and sale of medicines, with all existing traditional Chinese medicines being self-produced [1] - There is no third-party production involved in the company's products, ensuring quality and brand integrity [1] - The company has communicated with Tongrentang Group regarding the situation to jointly protect brand reputation [1]

Core Viewpoint - A product claiming to be "99% pure Antarctic krill oil" from "Beijing Tongrentang" actually contains no krill oil, misleading consumers and raising concerns about brand integrity and consumer protection [1][4]. Group 1: Product Misrepresentation - The product's packaging prominently features "Beijing Tongrentang," leading consumers to believe it is from a reputable source, while the actual brand is "Tongrentang (TRT)" [1]. - The product claims to have a phospholipid content of 43%, but it contains no krill oil at all, undermining the quality associated with the Tongrentang brand [1][4]. - The infringing company, Beijing Tongrentang (Sichuan) Health Industry Co., Ltd., is being sued by Beijing Tongrentang Health Pharmaceutical Co., Ltd. for trademark infringement [1][5]. Group 2: Manufacturer's Accountability - The manufacturer, Anhui Habao Pharmaceutical Co., Ltd., has faced multiple administrative penalties in the past three years for label non-compliance and advertising violations [3]. - The out-of-line pricing of the product raises questions about the manufacturer's practices, suggesting a lack of transparency and accountability [3][4]. - The infringing company claims ignorance of the misleading packaging, but the circumstances suggest otherwise, indicating potential complicity [3]. Group 3: Brand Integrity and Consumer Trust - The "Tongrentang universe" is described as a chaotic marketplace where many products misuse the Tongrentang name, threatening the brand's reputation built over centuries [4]. - Beijing Tongrentang emphasizes the importance of maintaining its brand integrity and has repeatedly stated that it has never authorized the use of its trademark by subsidiary companies [4]. - The company is committed to legal action to protect its brand and consumer rights, highlighting the need for stricter regulatory oversight to prevent such abuses [5][7].

百年老字号同仁堂，近日因一款"南极磷虾油"产品被推上舆论风口。上海市消保委检测发现，该产品标 识磷脂含量43%，实际检测结果为0，涉嫌虚假宣传。然而，同仁堂集团却回应称"没有这款产品"。一 场"造假"罗生门的背后，折射出这家药界老字号在品牌管控、业绩压力与治理结构上的多重风险。 一、产品造假还是品牌失控？"贴牌乱象"侵蚀信任根基 此次涉事产品标注为"北京同仁堂99%高纯南极磷虾油"，经销商为北京同仁堂（四川）健康药业有限公 司——一家由同仁堂集团间接持股的"孙公司"。尽管集团迅速撇清关系，称产品非其出品，但消费者在 电商平台以"北京同仁堂"为关键词搜索，仍可见大量贴牌商品，从保健食品到日用品，覆盖众多品类。 这类贴牌模式虽在短期内带来授权收入，却隐藏着巨大风险：一旦产品质量出现问题，消费者往往将矛 头直指"同仁堂"品牌本身。集团虽屡发声明禁止下属公司滥用商标，但实操中监管显然乏力。品牌价值 在一次次"贴牌—出事—否认"的循环中被不断稀释，长远来看，这种透支信誉的做法恐将动摇其百年积 累的信任根基。 二、业绩连续下滑，短视行为背后的经营压力 同仁堂近年财务表现并不乐观。2025年三季报显示，公司营收与净利润双双 ...

Core Viewpoint - The Shanghai Consumer Protection Committee has revealed that "Beijing Tongrentang" krill oil is suspected of being counterfeit, with the manufacturer admitting that the product does not contain the claimed "Antarctic krill oil" [2][3]. Group 1: Company Accountability - Anhui Habao Pharmaceutical Co., Ltd. stated that the disputed product was custom-ordered by Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. at a price significantly below normal levels [2]. - The Shanghai Consumer Protection Committee found that the involved companies engaged in deceptive practices, violating consumer rights and market integrity principles [2]. - Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. denied knowledge of the alleged counterfeiting and attempted to evade responsibility during discussions with the committee [2]. Group 2: Consumer Protection Actions - The Shanghai Consumer Protection Committee urged Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. to conduct a self-examination, apologize to consumers, and recall the problematic products [3]. - The committee has notified relevant regulatory authorities in Sichuan about the situation [3]. - Beijing Tongrentang has ordered the cessation of sales of the disputed product and initiated a full process review and traceability [3].

Core Viewpoint - The investigation into 15 popular Antarctic krill oil products revealed significant discrepancies in labeling and actual content, raising concerns about consumer safety and the implications of the "private label" model in the industry [1][2] Group 1: Product Testing and Findings - The Shanghai Consumer Protection Commission commissioned a study that found a product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" contained 0% phospholipid, despite claiming a 43% phospholipid content [1] - The product is manufactured by Anhui Habio Pharmaceutical Co., Ltd., and distributed by Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., Ltd. [1] Group 2: Brand Responsibility and Consumer Concerns - The incident has sparked widespread concern among consumers regarding the risks associated with the "private label" model, where well-known brands may not be the actual producers of the products [2] - The legal responsibility for product safety lies with both the brand owner and the actual manufacturer, as per the Food Safety Law Implementation Regulations [2]